NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. ( INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an upcoming poster presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, being hosted December 7 – 10, 2024 in San Diego, CA.
Details for the ASH 2024 presentation are as follows:
| Title: INB-100: Pilot Study of Donor Derived, ex-vivo Expanded/Activated Gamma-Delta T cell Infusion Following Haploidentical Hematopoietic Stem-Cell Transplantation and Post-Transplant Cyclophosphamide | |
| Presenter: Joseph McGuirk, DO, The University of Kansas Cancer Center | |
| Abstract #: 4823 | |
| Session Name: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III | |
| Date and Time: Monday, December 9, 2024, 6:00 PM - 8:00 PM PDT | |
The abstract will be available online and can be accessed via the conference websites at ASH Annual Meeting Abstracts. Reprints of the poster will also be accessible on the Events & Presentations page of IN8bio’s website following the presentations.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program, INB-100, is focused on AML evaluating haplo-matched allogenic gamma-delta T cells given to patients following a hematopoietic stem cell transplant. The company is also evaluating autologous DeltEx DRI gamma-delta T cells, in combination with standard of care, for glioblastoma. For more information about IN8bio, visit www.IN8bio.com.
Investors & Company Contacts:
Glenn Schulman, PharmD, MPH
203.494.7411
[email protected]
Patrick McCall
IN8bio, Inc.
646.933.5603
[email protected]
Media Contact:
Kimberly Ha
KKH Advisors
917.291.5744
[email protected]
